One‐stage implant in sacral neuromodulation for faecal incontinence – short‐term outcome from a prospective study
Colorectal Disease · 2024
DOI: 10.1111/codi.16936 ↗At a glance
Journal article in Colorectal Disease, 2024. Written by Jakob Duelund-Jakobsen and 5 co-authors. Institution: Pelvic Floor Unit, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. Major MEDLINE topics: Fecal Incontinence, Electric Stimulation Therapy, Quality of Life, Patient Satisfaction. Cited 11 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY 4.0). Funded by: The Danish Agency for Science, Technology and Innovation.
Topics: Inkontinenz
Abstract (original language)
Aim
Sacral neuromodulation (SNM) is approved for the treatment of faecal incontinence (FI) in a two‐stage technique. With standardized implantation, approximately 90% of patients undergo successful Stage I operation and proceed to a permanent implant (Stage II). The aim of this work was to explore the feasibility of SNM as a one‐stage procedure and report the 24‐week efficacy.
Method
This study included patients diagnosed with idiopathic FI or FI due to an external anal sphincter defect ≤160° and one or more episodes of FI per week despite maximal conservative therapy. Patients were offered a one‐stage procedure if a motor response of the external anal sphincter was achieved in three or more poles with at least one at ≤1.5 mA at lead placement. Patients were followed for 24 weeks. Their evaluation included the Wexner/St Mark's Incontinence Score, Faecal Incontinence Quality of Life score (FIQoL), a visual analogue scale (VAS) for assessing patient satisfaction and a bowel habit diary.
Results
Seventy‐three patients with a median age of 60 years (interquartile range 50–69 years) completed this prospective study. Episodes of FI were significantly reduced at the 24‐week follow‐up, from 13 (8–23) at baseline to 2 (0–5) ( p ‐value = 0002). A ≥50% reduction in the number of FI episodes was achieved in 92% of participants. The Wexner score improved significantly from 16 (14–17) at baseline to 9 (5–13) ( p ‐value < 0.001), and the St Mark's score improved significantly from 18 (16–20) to 11 (7–16) ( p ‐value < 0.001). All domains in the FIQoL score and VAS for patient satisfaction improved significantly following the one‐stage procedure.
Conclusion
A one‐stage implantation procedure is feasible in selected patients with FI, significantly improving continence, quality of life and patient satisfaction after 24 weeks of follow‐up.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Pelvic Floor Unit, Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
- Department of Gastroenterological Surgery, National Advisory Board of Incontinence and Pelvic Floor Health of Norway, University Hospital of North Norway, Tromsoe, Norway.
- Department of Clinical Medicine, Arctic University of North Norway, Tromsoe, Norway.
- Department of Surgical and Medical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark.
ORCID profiles: Lilli Lundby
Funding
- The Danish Agency for Science, Technology and Innovation
Cite
APA
Duelund-Jakobsen, J., Buntzen, S., Lundby, L., Laurberg, S., Sørensen, M., & Rydningen, M. (2024). One‐stage implant in sacral neuromodulation for faecal incontinence – short‐term outcome from a prospective study. Colorectal Disease. https://doi.org/10.1111/codi.16936
Vancouver
Duelund-Jakobsen J, Buntzen S, Lundby L, Laurberg S, Sørensen M, Rydningen M. One‐stage implant in sacral neuromodulation for faecal incontinence – short‐term outcome from a prospective study. Colorectal Disease. 2024. doi:10.1111/codi.16936
BibTeX
@article{DuelundJakobsen2024,
author = {Duelund-Jakobsen, Jakob and Buntzen, Steen and Lundby, Lilli and Laurberg, Søren and Sørensen, Michael and Rydningen, Mona},
title = {One‐stage implant in sacral neuromodulation for faecal incontinence – short‐term outcome from a prospective study},
journal = {Colorectal Disease},
year = {2024},
doi = {10.1111/codi.16936}
}
EUVIMED